Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer

• DOI: 10.1371/journal.pone.0189410
• Publication Date: 2017-12-11T13:27:24Z
• Authors: Eric S. Kim; Andrea M. Baran; Esther L. Mondo; Thomas D. Rodgers; Gradon C. Nielsen; David W. Dougherty; Kishan J. Pandya; David Q. Rich; Edwin van Wijngaa...
• Keywords: Carboplatin

Introduction Carboplatin is widely used to treat lung cancer in the United States as an alternative cisplatin. Several studies have demonstrated that cisplatin-based regimen associated with a high frequency of thromboembolic complications. However, there has been limited investigation directly comparing risk events (TEEs) between cisplatin- and carboplatin-treated patients cancer. Methods All treated cisplatin or carboplatin at Wilmot Cancer Center, University Rochester 2011 2014 were included. Patient characteristics including exposure (cisplatin vs. carboplatin) outcome (TEEs time first dose 4 weeks after last dose) collected by reviewing electronic medical records. A Fisher's exact test was compare proportion incident TEEs groups. The TEE compared assessed using multiple logistic regression. Results Among 415 subjects, 317 (76.4%) received 98 (23.6%) In group, 10.9% (33/302) evaluable developed treatment-related 14.7% (14/95) group. There no significant difference developing two groups (P = 0.32). 15.2% carboplatin-related arterial thromboses none Conclusions incidence without Potential use prophylactic anticoagulation all platinum-treated should be further investigated.